Advanced search
Publication Cover
Tissue Barriers Volume 10, 2022 - Issue 1
Submit an article Journal homepage
8,425
Views
8
CrossRef citations to date
0
Altmetric
Review

Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials

Daisuke Kyunoa Department of Pathology, Sapporo Medical University, Sapporo, Japan;b Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4672-535XView further author information
ORCID Icon,
Akira Takasawaa Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
,
Kumi Takasawaa Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
,
Yusuke Onoa Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
,
Tomoyuki Aoyamaa Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
,
Kazufumi Magaraa Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
,
Yuna Nakamoria Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
,
Ichiro Takemasab Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, JapanView further author information
&
Makoto Osanaia Department of Pathology, Sapporo Medical University, Sapporo, JapanView further author information
 show all
Article: 1967080 | Received 24 May 2021, Accepted 07 Aug 2021, Published online: 05 Sep 2021

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W.M. De Groof & Nick Devoogdt. (2023) Current status and future expectations of nanobodies in oncology trials. Expert Opinion on Investigational Drugs 32:8, pages 705-721.
Read now

Articles from other publishers (7)

Daniele Lavacchi, Sara Fancelli, Eleonora Buttitta, Gianmarco Vannini, Alessia Guidolin, Costanza Winchler, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Marco Brugia, Fabio Cianchi, Serena Pillozzi, Giandomenico Roviello & Lorenzo Antonuzzo. (2023) Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. International Journal of Molecular Sciences 24:5, pages 4877.
Crossref
Samer A. Srour & Serkan Akin. (2023) Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. Journal of Immunotherapy and Precision Oncology 6:1, pages 19-30.
Crossref
Fujun Wang, Yao Yang, Xiuzhen Du, Xiaoying Zhu, Yanjiao Hu, Changyu Lu, Lei Sui, Han Zhao, Kejuan Song & Qin Yao. (2023) Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours. BMC Cancer 23:1.
Crossref
De-Wen Wang, Wei-Han Zhang, Galiullin Danil, Kun Yang & Jian-Kun Hu. (2022) The role and mechanism of claudins in cancer. Frontiers in Oncology 12.
Crossref
Weijie Cao, Haizhou Xing, Yingmei Li, Wenliang Tian, Yongping Song, Zhongxing Jiang & Jifeng Yu. (2022) Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomarker Research 10:1.
Crossref
Ming Cai, Wei-Jian Ni, Ying-Hong Wang, Jing-Ji Wang & Hong Zhou. (2022) Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors. Frontiers in Oncology 12.
Crossref
Luisa Chocarro, Hugo Arasanz, Leticia Fernández-Rubio, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucía Teijeira, Maider Garnica, Idoia Morilla, Maite Martínez-Aguillo, Sergio Piñeiro-Hermida, Pablo Ramos, Juan José Lasarte, Ruth Vera, Grazyna Kochan & David Escors. (2022) CAR-T Cells for the Treatment of Lung Cancer. Life 12:4, pages 561.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.